Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023 08:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 13, 2023 07:05 ET
|
Celcuity Inc.
Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a...
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
November 06, 2023 07:30 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
November 01, 2023 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Celcuity to Host Virtual Science Day for Investors
September 07, 2023 16:05 ET
|
Celcuity Inc.
Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor typesDiscussion of the...
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial
August 22, 2023 16:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
August 22, 2023 16:01 ET
|
Celcuity Inc.
- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 ...
Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 10, 2023 16:04 ET
|
Celcuity Inc.
Phase 3 VIKTORIA-1 clinical trial is now recruiting patients at nearly 200 sites in 20 countriesPresented updated results from Phase 1b study of gedatolisib in treatment-naïve advanced breast cancer...
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
August 03, 2023 07:30 ET
|
Celcuity Inc.
MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it...
Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
July 31, 2023 08:00 ET
|
Celcuity Inc.
MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that...